{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:08:17Z","timestamp":1780380497942,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40261-022-01230-x","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T21:03:40Z","timestamp":1670533420000},"page":"45-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Safety and Effectiveness of Erenumab in Patients with Migraine: A Systematic Review and Single-Arm Meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7268-6695","authenticated-orcid":false,"given":"Fernanda Ferreira","family":"Bomtempo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeka Bustamante","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Isadora","family":"Cenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Borges","family":"Nager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo Mota","family":"Telles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"1230_CR1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia Int J Headache. 2018 Jan;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"10258","key":"1230_CR2","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204\u201322.","journal-title":"The Lancet"},{"issue":"1","key":"1230_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, on behalf of Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137.","journal-title":"J Headache Pain"},{"issue":"8","key":"1230_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501\u201314.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"1230_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0333102421989601","volume":"41","author":"K Drellia","year":"2021","unstructured":"Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. Cephalalgia Int J Headache. 2021;41(7):851\u201364.","journal-title":"Cephalalgia Int J Headache."},{"issue":"13","key":"1230_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.846717","volume":"28","author":"L Sette","year":"2022","unstructured":"Sette L, Caponnetto V, Ornello R, Ne\u017e\u00e1dal T, \u010ctrn\u00e1ct\u00e1 D, \u0160\u00edpkov\u00e1 J, Matou\u0161ov\u00e1 Z, Sacco S. Acute medication use in patients with migraine treated with monoclonal antibodies acting on the CGRP pathway: results from a multicenter study and proposal of a new index. Front Neurol. 2022;28(13): 846717.","journal-title":"Front Neurol"},{"issue":"1","key":"1230_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-021-01333-4","volume":"22","author":"S Bottiroli","year":"2021","unstructured":"Bottiroli S, De Icco R, Vaghi G, Pazzi S, Guaschino E, Allena M, Ghiotto N, Martinelli D, Tassorelli C, Sances G. Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain. 2021;22(1):114 (Erratum in: J Headache Pain. 2021 Nov 3;22(1):131).","journal-title":"J Headache Pain"},{"key":"1230_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.895476","volume":"13","author":"M Nowaczewska","year":"2022","unstructured":"Nowaczewska M, Straburzy\u0144ski M, Waliszewska-Pros\u00f3\u0142 M, Meder G, Janiak-Kiszka J, Ka\u017amierczak W. Cerebral blood flow and other predictors of responsiveness to erenumab and fremanezumab in migraine\u2014a real-life study. Front Neurol. 2022;13: 895476.","journal-title":"Front Neurol"},{"issue":"9","key":"1230_CR9","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, et al. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache. 2021;61(9):1351\u201363.","journal-title":"Headache"},{"issue":"1","key":"1230_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10194-022-01408-w","volume":"23","author":"R Ornello","year":"2022","unstructured":"Ornello R, Baraldi C, Guerzoni S, Lambru G, Andreou AP, Raffaelli B, Gendolla A, Barbanti P, Aurilia C, Egeo G, Cevoli S, Favoni V, Vernieri F, Altamura C, Russo A, Silvestro M, Valle ED, Mancioli A, Ranieri A, Alfieri G, Latysheva N, Filatova E, Talbot J, Cheng S, Holle D, Scheffler A, Ne\u017e\u00e1dal T, \u010ctrn\u00e1ct\u00e1 D, \u0160\u00edpkov\u00e1 J, Matou\u0161ov\u00e1 Z, Casalena A, Maddestra M, Viola S, Affaitati G, Giamberardino MA, Pistoia F, Reuter U, Sacco S. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. J Headache Pain. 2022;23(1):38.","journal-title":"J Headache Pain"},{"key":"1230_CR11","unstructured":"U.S. Food and Drug Administration (FDA). AIMOVIGTM (erenumab-aooe) injection, for subcutaneous use Initial U.S. Approval: 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761077s000lbl.pdf. Accessed 10 June 2022."},{"issue":"10","key":"1230_CR12","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1007\/s10072-021-05105-5","volume":"42","author":"MM Cainazzo","year":"2021","unstructured":"Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci. 2021;42(10):4193\u2013202.","journal-title":"Neurol Sci"},{"issue":"7","key":"1230_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2662","volume":"12","author":"M Nsaka","year":"2022","unstructured":"Nsaka M, Scheffler A, Wurthmann S, Schenk H, Kleinschnitz C, Glas M, Holle D. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies. Brain Behav. 2022;12(7): e2662.","journal-title":"Brain Behav"},{"issue":"11\u201312","key":"1230_CR14","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/03331024211014616","volume":"41","author":"AR Gantenbein","year":"2021","unstructured":"Gantenbein AR, Agosti R, Gobbi C, Fl\u00fcgel D, Schankin CJ, Viceic D, et al. Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment\u2014a real-life cohort study. Cephalalgia. 2021;41(11\u201312):1181\u20136.","journal-title":"Cephalalgia"},{"key":"1230_CR15","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions\u00a0version 6.3. Cochrane, 2022. www.training.cochrane.org\/handbook. Assessed 8 June 2022."},{"issue":"1","key":"1230_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6030\/1939-067X-3.1.8","volume":"3","author":"SR Evans","year":"2010","unstructured":"Evans SR. Clinical trial structures. J Exp Stroke Transl Med. 2010;3(1):8\u201318.","journal-title":"J Exp Stroke Transl Med."},{"key":"1230_CR17","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa, ON: Ottawa Hospital Research Institute, 2021. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 10 June 2022."},{"issue":"19","key":"1230_CR18","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.3390\/jcm10194425","volume":"10","author":"Z Maraia","year":"2021","unstructured":"Maraia Z, Ricci D, Rocchi MBL, Moretti A, Bufarini C, Cavaliere A, Peverini M. Real-life analysis with erenumab: first target therapy in the episodic and chronic migraine\u2019s prophylaxis. J Clin Med. 2021;10(19):4425.","journal-title":"J Clin Med"},{"issue":"13","key":"1230_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.869677","volume":"13","author":"G Pellitteri","year":"2022","unstructured":"Pellitteri G, Pez S, Nilo A, Surcinelli A, Gigli GL, Lettieri C, et al. Erenumab impact on sleep assessed with questionnaires and home-polysomnography in patients with migraine: the ERESON Study. Front Neurol. 2022;13(13): 869677.","journal-title":"Front Neurol"},{"issue":"3","key":"1230_CR20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1136\/jnnp-2021-327480","volume":"93","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Reuter U, Goadsby PJ, Paiva da Silva Lima G, Mondal S, Wen S, et al. Two-year efficacy and safety of erenumab in participants with episodic migraine and 2\u20134 prior preventive treatment failures: results from the LIBERTY study. J Neurol Neurosurg Psychiatry. 2022;93(3):254\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"1230_CR21","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716\u201325.","journal-title":"Eur J Neurol"},{"issue":"5","key":"1230_CR22","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1212\/WNL.0000000000010019","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, et al. One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology. 2020;95(5):e469\u201379.","journal-title":"Neurology"},{"issue":"4","key":"1230_CR23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/head.14096","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, et al. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine. Headache J Head Face Pain. 2021;61(4):653\u201361.","journal-title":"Headache J Head Face Pain."},{"issue":"6","key":"1230_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein SD, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. Cephalalgia. 2020;40(6):543\u201353.","journal-title":"Cephalalgia"},{"issue":"1","key":"1230_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-022-01433-9","volume":"23","author":"CK Cullum","year":"2022","unstructured":"Cullum CK, Do TP, Ashina M, Bendtsen L, Hugger SS, Iljazi A, et al. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. J Headache Pain. 2022;23(1):61.","journal-title":"J Headache Pain"},{"issue":"8","key":"1230_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2260","volume":"11","author":"C Baraldi","year":"2021","unstructured":"Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S. Predictors of response to erenumab after 12 months of treatment. Brain Behav. 2021;11(8): e2260.","journal-title":"Brain Behav"},{"issue":"8","key":"1230_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40261-021-01059-w","volume":"41","author":"M Eghtesadi","year":"2021","unstructured":"Eghtesadi M, Leroux E, Pag\u00e9 G. Real-life response to erenumab in a therapy-resistant case series of migraine patients from the Province of Qu\u00e9bec, Eastern Canada. Clin Drug Investig. 2021;41(8):733\u20139.","journal-title":"Clin Drug Investig"},{"issue":"12","key":"1230_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.805334","volume":"10","author":"J Schoenen","year":"2021","unstructured":"Schoenen J, Timmermans G, Nonis R, Manise M, Fumal A, G\u00e9rard P. Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes. Front Neurol. 2021;10(12): 805334.","journal-title":"Front Neurol"},{"issue":"1","key":"1230_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-021-01313-8","volume":"22","author":"K Hirata","year":"2021","unstructured":"Hirata K, Sakai F, Takeshima T, Imai N, Matsumori Y, Yoshida R, et al. Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial. J Headache Pain. 2021;22(1):110.","journal-title":"J Headache Pain"},{"issue":"1","key":"1230_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32.","journal-title":"J Headache Pain"},{"issue":"4","key":"1230_CR31","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/head.14291","volume":"62","author":"WJ Becker","year":"2022","unstructured":"Becker WJ, Spacey S, Leroux E, Giammarco R, Gladstone J, Christie S, et al. A real-world, observational study of erenumab for migraine prevention in Canadian patients. Headache J Head Face Pain. 2022;62(4):522\u20139.","journal-title":"Headache J Head Face Pain."},{"issue":"6","key":"1230_CR32","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026\u201337.","journal-title":"Cephalalgia"},{"issue":"1","key":"1230_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s10194-022-01426-8","volume":"23","author":"H Schenk","year":"2022","unstructured":"Schenk H, Holle D, Nsaka M, Kleinschnitz C, Glas M, Scheffler A. Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study. J Headache Pain. 2022;23(1):55.","journal-title":"J Headache Pain"},{"issue":"4","key":"1230_CR34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","volume":"79","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, et al. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety. Drugs. 2019;79(4):417\u201331.","journal-title":"Drugs"},{"issue":"52","key":"1230_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018483","volume":"98","author":"C Zhu","year":"2019","unstructured":"Zhu C, Guan J, Xiao H, Luo W, Tong R. Erenumab safety and efficacy in migraine. Medicine (Baltimore). 2019;98(52): e18483.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"1230_CR36","first-page":"2751","volume":"43","author":"X Wang","year":"2022","unstructured":"Wang X, He Q, Wen D, Ma L, You C. Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2022;43(4):2751\u20138.","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol."},{"issue":"1","key":"1230_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12883-020-01633-3","volume":"20","author":"H Deng","year":"2020","unstructured":"Deng H, Li GG, Nie H, Feng YY, Guo GY, Guo WL, et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine\u2014an updated systematic review and meta-analysis. BMC Neurol. 2020;20(1):57.","journal-title":"BMC Neurol"},{"issue":"427","key":"1230_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117505","volume":"15","author":"AT Masoud","year":"2021","unstructured":"Masoud AT, Hasan MT, Sayed A, Edward HN, Amer AM, Naga AE, et al. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): a network meta-analysis of randomized controlled trials. J Neurol Sci. 2021;15(427): 117505.","journal-title":"J Neurol Sci"},{"key":"1230_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106893","volume":"209","author":"P Soni","year":"2021","unstructured":"Soni P, Chawla E. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis. Clin Neurol Neurosurg. 2021;209: 106893.","journal-title":"Clin Neurol Neurosurg"},{"key":"1230_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.649143","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Chen Y, Song J, You C. Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis. Front Pharmacol. 2021;12: 649143.","journal-title":"Front Pharmacol"},{"issue":"9","key":"1230_CR41","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1177\/0333102419829007","volume":"39","author":"D Xu","year":"2019","unstructured":"Xu D, Chen D, Zhu LN, Tan G, Wang HJ, Zhang Y, et al. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine\u2014a meta-analysis of randomized controlled trials. Cephalalgia Int J Headache. 2019;39(9):1164\u201379.","journal-title":"Cephalalgia Int J Headache."},{"issue":"12","key":"1230_CR42","first-page":"2097","volume":"39","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Liu Y, Zhao J, Han Q, Liu L, Shen X. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2018;39(12):2097\u2013106.","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol."},{"key":"1230_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.105900","volume":"195","author":"YW Alasad","year":"2020","unstructured":"Alasad YW, Asha MZ. Monoclonal antibodies as a preventive therapy for migraine: a meta-analysis. Clin Neurol Neurosurg. 2020;195: 105900.","journal-title":"Clin Neurol Neurosurg"},{"issue":"14","key":"1230_CR44","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1177\/0333102419888222","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, et al. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia. 2019;39(14):1798\u2013808.","journal-title":"Cephalalgia"},{"key":"1230_CR45","doi-asserted-by":"crossref","unstructured":"Ashina M, Reuter U, Dodick D, Zhang F, Ritter S, Stites T, Paiva da Silva Lima G, Arkuszewski M, Goadsby P. Long-term safety and tolerability of erenumab in episodic migraine: a pooled analysis from two clinical trials and their extension phases (P3-2.005). Neurology. 2022;98(18 Supplement):324.","DOI":"10.1212\/WNL.98.18_supplement.324"},{"issue":"8","key":"1230_CR46","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/03331024221075621","volume":"42","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Zhang F, Starcevic Manning M, Hu Z, Hsu CP, Chen PW, Peng C, Loop B, Mytych DT, Paiva ds Silva Lima G. Immunogenicity of erenumab: a pooled analysis of six placebo-controlled trials with long-term extensions. Cephalalgia. 2022;42(8):749\u201360.","journal-title":"Cephalalgia"},{"issue":"4","key":"1230_CR47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/14740338.2021.1866537","volume":"20","author":"L Pellesi","year":"2021","unstructured":"Pellesi L, De Icco R, Alawie HY, Andersen M, Liang D, Amirguliyev S, et al. A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. Expert Opin Drug Saf. 2021;20(4):467\u201374.","journal-title":"Expert Opin Drug Saf"},{"issue":"20","key":"1230_CR48","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019;92(20):e2309\u201320.","journal-title":"Neurology"},{"issue":"3","key":"1230_CR49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6TM) across episodic and chronic migraine. Cephalalgia. 2011;31(3):357\u201367.","journal-title":"Cephalalgia"},{"issue":"8","key":"1230_CR50","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559\u201366.","journal-title":"Neurology"},{"issue":"6","key":"1230_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40695-020-00059-8","volume":"6","author":"JM Pavlovi\u0107","year":"2020","unstructured":"Pavlovi\u0107 JM. The impact of midlife on migraine in women: summary of current views. Womens Midlife Health. 2020;6(6):11.","journal-title":"Womens Midlife Health."},{"issue":"1","key":"1230_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s10194-022-01470-4","volume":"23","author":"C Lampl","year":"2022","unstructured":"Lampl C, Kraus V, Lehner K, Loop B, Chehrenama M, Maczynska Z, Ritter S, Klatt J, Snellman J. Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials. J Headache Pain. 2022;23(1):104.","journal-title":"J Headache Pain"},{"issue":"17","key":"1230_CR53","doi-asserted-by":"crossref","first-page":"e1897","DOI":"10.1212\/WNL.0000000000201008","volume":"99","author":"LS de Vries","year":"2022","unstructured":"de Vries LS, van der Arend BWH, Maassen VanDenBrink A, Terwindt GM. Blood pressure in patients with migraine treated with monoclonal anti-CGRP (Receptor) antibodies: a prospective follow-up study. Neurology. 2022;99(17):e1897\u2013904.","journal-title":"Neurology"},{"issue":"1","key":"1230_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-022-01424-w","volume":"23","author":"AO G\u00e9rard","year":"2022","unstructured":"G\u00e9rard AO, Merino D, Van Obberghen EK, Rocher F, Destere A, Lant\u00e9ri-Minet M, Drici MD. Calcitonin gene-related peptide-targeting drugs and Raynaud\u2019s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. J Headache Pain. 2022;23(1):53.","journal-title":"J Headache Pain"},{"issue":"5","key":"1230_CR55","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s42399-020-00300-5","volume":"2","author":"N Joshi","year":"2020","unstructured":"Joshi N, McAree M, Klimowich K, Cahill K, Janora D. Oral candidiasis in a migraine patient taking erenumab and galcanezumab: a case report. Compr Clin Med. 2020;2(5):658\u201361.","journal-title":"Compr Clin Med"},{"issue":"4","key":"1230_CR56","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):382\u201390.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1230_CR57","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, et al. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021;22(1):154.","journal-title":"J Headache Pain"},{"issue":"8","key":"1230_CR58","first-page":"3297","volume":"42","author":"E De Matteis","year":"2021","unstructured":"De Matteis E, Affaitati G, Frattale I, Caponnetto V, Pistoia F, Giamberardino MA, et al. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2021;42(8):3297\u2013303.","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol."},{"issue":"6","key":"1230_CR59","first-page":"3823","volume":"43","author":"S Guerzoni","year":"2022","unstructured":"Guerzoni S, Baraldi C, Pensato U, Favoni V, Lo Castro F, Cainazzo MM, et al. Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2022;43(6):3823\u201330.","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol."},{"issue":"6","key":"1230_CR60","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1212\/CPJ.0000000000001112","volume":"11","author":"F Schiano di Cola","year":"2021","unstructured":"Schiano di Cola F, Caratozzolo S, Venturelli E, Balducci U, Sidoti V, Pari E, et al. Erenumab discontinuation after 12-month treatment: a multicentric, observational real-life study. Neurol Clin Pract. 2021;11(6):e834\u20139.","journal-title":"Neurol Clin Pract."},{"issue":"1","key":"1230_CR61","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s10194-021-01368-7","volume":"22","author":"M Terhart","year":"2021","unstructured":"Terhart M, Mecklenburg J, Neeb L, Overeem LH, Siebert A, Steinicke M, Raffaelli B, Reuter U. Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain. 2021;22(1):158.","journal-title":"J Headache Pain"},{"issue":"11","key":"1230_CR62","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/sim.1183","volume":"21","author":"PP Glasziou","year":"2002","unstructured":"Glasziou PP, Sanders SL. Investigating causes of heterogeneity in systematic reviews. Stat Med. 2002;21(11):1503\u201311.","journal-title":"Stat Med"},{"issue":"2","key":"1230_CR63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00002018-200730020-00001","volume":"30","author":"RO Day","year":"2007","unstructured":"Day RO, Williams KM. Open-label extension studies: do they provide meaningful information on the safety of new drugs? Drug Saf. 2007;30(2):93\u2013105.","journal-title":"Drug Saf"},{"issue":"3","key":"1230_CR64","doi-asserted-by":"publisher","first-page":"368","DOI":"10.14236\/jhi.v22i3.177","volume":"22","author":"S de Lusignan","year":"2015","unstructured":"de Lusignan S, Crawford L, Munro N. Creating and using real-world evidence to answer questions about clinical effectiveness. J Innov Health Inform. 2015;22(3):368\u201373.","journal-title":"J Innov Health Inform."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01230-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01230-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01230-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T03:16:00Z","timestamp":1728530160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01230-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1230"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01230-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"16 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship and\/or publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"No ethical approval was required because this study synthesized and analyzed data from already published studies, in which informed consent was obtained by primary investigators.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All data generated or analyzed during this study are included in this published article (and its electronic supplemental material).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"FFB: study conception and design, acquisition of data, analysis and interpretation of data, drafting of manuscript and critical revision. JPMT: analysis and interpretation of results and critical revision. RBR: acquisition of data and critical revision. GIC: draft manuscript preparation. GBN: draft manuscript preparation. All authors have read and agreed to the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}